Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France
European Psychiatry November 17, 2023 E. Gaudre Wattinne, L. Mekaoui, M. Rothärmel et al. 1 citation
In a French early-access program, 66 patients with treatment-resistant depression received esketamine nasal spray. Most patients (79%) had a severe current depressive episode, the median disease duration was 12.2 years, and the current episode lasted a median of 2.6 years. All patients had tried at least two antidepressants (mean 4.2). Esketamine was started in full hospitalization for 55% of patients and in day hospitalization for 45%. Common side effects, occurring in more than 10% of patients, included dizziness, sedation, sleepiness, anxiety, and dissociation; these were typically brief and appeared after administration. The safety profile matched that seen in clinical trials.